RVMD · Revolution Medicines, Inc.

Track RVMD — free

$205.00 +0.52 (+0.25%) At close · Sep 30

Russell 1000 member Rebalance outlook locked

Market Cap

$43.93B

214.34M

Volume · Sep 30 1.85M Avg daily vol (3M) 1.97M

Up next

Next earnings call

Nov 4, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 5, 2026

Q2 2026 earnings call transcript

call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$1.77B

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-2.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$3.94B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+11.8%

Year over year · more shares

Price change (1Y)

+343.8%

Trailing year

Short interest

4.5%

Latest settlement · 7.2 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Poor Quant / Vol High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +42%

above

Price vs 50-day avg +2%

above

RSI (14) 54

neutral

MACD trend Positive

52-week position 90%

near high

Momentum

relative strength

Very Strong

1-month return −1%

trailing

6-month return +111%

trailing

YTD return +157%

this year

Relative strength +98%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $201 › 200d $144 — 50d above 200d

Institutional flow Accumulating

+34% holders QoQ · +246 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

4.51% of float · ▼ -0.6% MoM · 7.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

706 holders — near 3-yr high, broad support

Squeeze score 62

elevated · 0–100

Fundamentals

Poor

EPS growth −66%

Y/Y

Free cash flow $-913.7M

Quant / Vol

risk profile

High

Volatility 66%

annualized · 1-yr

Max drawdown −25%

past year

ATR 3.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Jun 30, 2026

GAAP operating expenses · full-year 2026 GAAP Initiated $2.1B – $2.2B

Non-cash stock-based compensation expense · full-year 2026 Initiated $270M – $290M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+42% Bullish

Price vs 50-day avg

+2% Bullish

RSI (14)

54 Neutral

MACD trend

Positive Bullish

52-week position

90% Bullish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $201 › 200d $144 — 50d above 200d

Institutional flow Accumulating

+34% holders QoQ · +246 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

4.51% of float · ▼ -0.6% MoM · 7.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

706 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $46 Now $204 · 90% Range high $221

vs 200-day avg +42% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RVMD Revolution Medicines, Inc. this stock	$43.93B	+156.7%	—	—	4.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+16.2%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-2.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.9%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

706

% held: 107.0%
Net QoQ: +12.8M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

530

View

Short & Settlement

Short Interest Falling

Shares short

9.7M

Days to cover: 7.2d
Change: -58.0K sh

View

Short Volume

Short vol %

69%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

404

Value: $83.1K
As of: Sep 1, 2026

View

Off-Exchange

Off-exchange %

55.7%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

Net income (FY): $-1.1B
EPS diluted: $-5.95

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 1, 2026
This year: 14

View

Proposed Sales

Value

$1.3M

Shares: 6.3K
Filed: Sep 29, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 5, 2026

View

Performance

	5D	20D	120D	MTD	YTD
RVMD	+6.0%	-0.5%	+111.4%	-0.5%	+156.7%
SPY	-1.2%	-0.4%	+13.1%	-0.4%	+12.1%
vs SPY	+7.2%	-0.2%	+98.3%	-0.2%	+144.7%

Key facts CIK 1628171 CUSIP 76155X100 13F (30d) 17 filings 14 filers Visit website Investor relations

RVMD · Revolution Medicines, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance